Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SciVac set to acquire VBI Vaccines
December 2015
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, Mass.—VBI Vaccines Inc. and SciVac Therapeutics Inc. have signed an agreement and plan of merger under which SciVac will acquire VBI. A wholly owned SciVac subsidiary will merge with and into VBI, with the latter surviving the merger as a wholly owned subsidiary of SciVac, and SciVac’s name will change to VBI Vaccines Inc. At the time of the merger, each share of VBI common stock will be converted into the right to receive 20.808356 common shares of SciVac. Following the merger, VBI shareholders will hold approximately 42 percent of the issued and outstanding shares and voting power of the combined company. Both companies’ boards of directors have unanimously approved the agreement and merger. The transaction is subject to customary closing conditions, including approval from shareholders of both SciVac and VBI.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.